Dogwood Therapeutics, Inc. (NASDAQ: DWTX)

Virios Therapeutics, a biotechnology company with the ticker symbol VIRI, operates in the healthcare industry with a focus on developing novel antiviral therapies for diseases triggered by a viral-induced abnormal immune response. The company's main business activities involve the development of IMC-1 and IMC-2, which are fixed-dose combinations of anti-herpes antivirals and celecoxib, intended to suppress herpesvirus activation and replication.

Virios Therapeutics generates revenue through the development and commercialization of its novel antiviral therapies, primarily through its products IMC-1 and IMC-2. These products are being developed to treat fibromyalgia (FM) and Long-COVID (LC), respectively. The company's customer base includes patients with FM and LC, as well as healthcare providers and researchers who are interested in the treatment of these diseases.

The company's fibromyalgia program has been granted fast-track review status by the U.S. Food and Drug Administration (FDA) for the treatment of FM. The company has completed a Phase 2a proof-of-concept study of IMC-1 in FM patients, which demonstrated statistically significant improvement in pain reduction compared to placebo. The company is currently planning to initiate a Phase 3 program for IMC-1, which will include two pivotal trials to demonstrate the safety and efficacy of IMC-1 in treating FM patients.

The company's Long-COVID program is focused on the development of IMC-2, which is being developed to treat patients with LC. The company has completed an open-label, exploratory trial of IMC-2 in LC patients, which demonstrated clinically and statistically significant improvement in symptoms of fatigue, orthostatic intolerance, anxiety, and pain. The company plans to initiate a Phase 2b study of IMC-2 in LC patients in the second half of 2024.

Virios Therapeutics is positioned as a leader in the development of novel antiviral therapies for the treatment of FM and LC. The company's IMC-1 and IMC-2 products have shown promising results in clinical trials, and the company is well-positioned to advance these products through late-stage clinical development and potential commercialization. The company's key competitors in the development of antiviral therapies for FM and LC include other biotechnology companies, such as Pfizer and GSK. However, Virios Therapeutics' novel approach to treating FM and LC, which involves combining anti-herpes antivirals with celecoxib, may provide a competitive advantage in the market.

The company's products, IMC-1 and IMC-2, are its primary offerings, and the company is focused on serving patients with FM and LC, as well as healthcare providers and researchers who are interested in the treatment of these diseases. The company's products are being developed to provide a new treatment option for patients with FM and LC, and the company is working to educate healthcare providers and researchers about the benefits of its products.